{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:32:19Z","timestamp":1792812739112,"version":"4.5.0"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:sec id=\"ab-doi250045-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Nicotinamide supplementation has been studied as a chemopreventive medication for reducing skin cancer risk, but large-scale data are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi250045-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the clinical efficacy of nicotinamide supplementation for skin cancer prevention in the general population and among solid organ transplant recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi250045-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted using electronic health record data (October 1, 1999, to December 31, 2024) from the Veterans Affairs Corporate Data Warehouse (CDW) of 33\u202f822 patients. Analyses were conducted from January 17, 2025, to May 9, 2025. Patients who were exposed to nicotinamide were propensity score matched based on the number and year of skin cancers after which treatment with nicotinamide was initiated, age, sex, self-reported race, exposure to acitretin, exposure to field therapy, history of chronic lymphocytic leukemia, and history of solid organ transplant. The index date was the first prescription of nicotinamide filled within the VA system. Stratified Cox models were used to investigate the association of nicotinamide with skin cancer development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi250045-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>Nicotinamide, 500 mg, twice daily for longer than 30 days as documented in the electronic health record.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi250045-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Time to the next skin cancer after baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi250045-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 12\u202f287 patients (mean [SD] age, 77.2 [8.9] years; 241 women [2.0%]; 31 [0.3%] American Indian or Alaska Native, 3 [&amp;amp;lt;0.1%] Asian, 13 [0.1%] Black or African American, 59 [0.5%] Native Hawaiian or other Pacific Islander, and 11\u202f662 [94.9%] White individuals) exposed to oral nicotinamide, 500 mg, twice daily for longer than 30 days who were matched to 21\u202f479 unexposed patients (mean [SD] age, 76.9 [8.7] years; 374 women [2.0%]; 49 [0.2%] American Indian or Alaska Native, 3 [&amp;amp;lt;0.1%] Asian, 16 [0.1%] Black or African American, 88 [0.4%] Native Hawaiian or other Pacific Islander, and 20\u202f517 [95.3%] White individuals). Within the matched dataset, there were 10\u202f994 instances of basal cell carcinoma after nicotinamide exposure and 12\u202f551 cutaneous squamous cell carcinoma (cSCC). A total of 1334 (3.9%) in the matched cohort were solid organ transplant recipients. Overall, there was a significant 14% reduction in skin cancer risk. When nicotinamide was initiated after a first skin cancer, the risk reduction rose to 54%, although this benefit declined with initiation following subsequent skin cancers. This risk reduction was seen for skin cancers overall, basal cell carcinoma, and cSCC, with the greatest risk reduction seen for cSCC. Among solid organ transplant recipients, no overall significant risk reduction was observed, although early nicotinamide use was associated with reduced cSCC incidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi250045-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The results of this cohort study suggest that there is a decreased risk of skin cancer among patients treated with nicotinamide, with the greatest effect seen when initiated after the first skin cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamadermatol.2025.3238","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:00:42Z","timestamp":1758121242000},"page":"1140","source":"Crossref","is-referenced-by-count":28,"title":["Nicotinamide for Skin Cancer Chemoprevention"],"prefix":"10.1001","volume":"161","author":[{"given":"Kimberly F.","family":"Breglio","sequence":"first","affiliation":[{"name":"Dermatology Division, Durham VA Medical Center, Durham, North Carolina"},{"name":"Cutaneous Surgery and Oncology, Department of Dermatology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katlyn M.","family":"Knox","sequence":"additional","affiliation":[{"name":"Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Hwang","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"},{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Dermatology Section, VA Boston Healthcare System, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Weiss","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Maas","sequence":"additional","affiliation":[{"name":"Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Madden","sequence":"additional","affiliation":[{"name":"State University of New York Downstate College of Medicine, Brooklyn"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaomin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca I.","family":"Hartman","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Dermatology Section, VA Boston Healthcare System, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Wheless","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Tennessee Valley Healthcare System VA Medical Center, Murfreesboro, Tennessee"},{"name":"Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"doi250045r1","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/DSS.0000000000002788","article-title":"Nicotinamide for keratinocyte carcinoma chemoprevention: a nationwide survey of Mohs surgeons.","volume":"47","author":"Desai","year":"2021","journal-title":"Dermatol Surg"},{"issue":"17","key":"doi250045r2","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1056\/NEJMoa1506197","article-title":"A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention.","volume":"373","author":"Chen","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"doi250045r3","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1056\/NEJMoa2203086","article-title":"Nicotinamide for skin-cancer chemoprevention in transplant recipients.","volume":"388","author":"Allen","year":"2023","journal-title":"N Engl J Med"},{"issue":"26","key":"doi250045r4","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1056\/NEJMc2303841","article-title":"Nicotinamide for skin-cancer chemoprevention in transplantation.","volume":"388","author":"Schmults","year":"2023","journal-title":"N Engl J Med"},{"issue":"26","key":"doi250045r5","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1056\/NEJMc2303841","article-title":"Nicotinamide for skin-cancer chemoprevention in transplantation.","volume":"388","author":"Trepanowski","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"doi250045r6","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00403-025-04296-7","article-title":"Nicotinamide for secondary keratinocyte carcinoma prevention in solid organ transplant recipients.","volume":"317","author":"Hwang","year":"2025","journal-title":"Arch Dermatol Res"},{"issue":"6","key":"doi250045r7","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jaad.2024.12.047","article-title":"Frequency and timing of multiple skin cancer development in five cohorts.","volume":"92","author":"Wheless","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi250045r8","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1001\/jamadermatol.2025.0001","article-title":"Risk of major adverse cardiovascular events following nicotinamide exposure.","volume":"161","author":"Wheless","year":"2025","journal-title":"JAMA Dermatol"},{"issue":"9","key":"doi250045r9","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1001\/jamadermatol.2021.2856","article-title":"Validity of using billing codes from electronic health records to estimate skin cancer counts.","volume":"157","author":"Anand","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"5 Pt 1","key":"doi250045r10","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/0190-9622(92)70100-T","article-title":"New primary nonmelanoma skin cancer in patients with a history of squamous cell carcinoma of the skin: implications and recommendations for follow-up.","volume":"26","author":"Frankel","year":"1992","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"doi250045r11","doi-asserted-by":"publisher","first-page":"e460","DOI":"10.1111\/jdv.17950","article-title":"Duration of acceptable delay between the time of diagnosis and treatment of melanoma, cutaneous squamous cell carcinoma and basal cell carcinoma.","volume":"36","author":"Alam","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"doi250045r12","doi-asserted-by":"publisher","DOI":"10.2196\/18001","article-title":"Development of phenotyping algorithms for the identification of organ transplant recipients: cohort study.","volume":"8","author":"Wheless","year":"2020","journal-title":"JMIR Med Inform"},{"issue":"3","key":"doi250045r13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1177\/12034754221078201","article-title":"Effect of nicotinamide in skin cancer and actinic keratoses chemoprophylaxis, and adverse effects related to nicotinamide: a systematic review and meta-analysis.","volume":"26","author":"Mainville","year":"2022","journal-title":"J Cutan Med Surg"},{"key":"doi250045r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2022.114826","article-title":"A bioluminescent-based probe for in vivo non-invasive monitoring of nicotinamide riboside uptake reveals a link between metastasis and NAD+ metabolism.","volume":"220","author":"Maric","year":"2023","journal-title":"Biosens Bioelectron"},{"issue":"4","key":"doi250045r15","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1056\/NEJMoa1204166","article-title":"Sirolimus and secondary skin-cancer prevention in kidney transplantation.","volume":"367","author":"Euvrard","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"doi250045r16","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jamadermatol.2022.3878","article-title":"Differences in skin cancer rates by transplanted organ type and patient age after organ transplant in White patients.","volume":"158","author":"Wheless","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"12","key":"doi250045r17","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1001\/jamadermatol.2021.4148","article-title":"Risks of multiple skin cancers in organ transplant recipients: a cohort study in 2 administrative data sets.","volume":"157","author":"Wehner","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"4","key":"doi250045r18","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jamadermatol.2014.3307","article-title":"Timing of subsequent new tumors in patients who present with basal cell carcinoma or cutaneous squamous cell carcinoma.","volume":"151","author":"Wehner","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"10","key":"doi250045r19","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1001\/jamadermatol.2021.3180","article-title":"Consensus-based recommendations on the prevention of squamous cell carcinoma in solid organ transplant recipients: a Delphi consensus statement.","volume":"157","author":"Massey","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"5","key":"doi250045r20","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/bjd.14662","article-title":"A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients.","volume":"175","author":"Chen","year":"2016","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi250045r21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/jamadermatol.2017.3631","article-title":"Chemoprevention of basal and squamous cell carcinoma with a single course of fluorouracil, 5%, cream: a randomized clinical trial.","volume":"154","author":"Weinstock","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"4","key":"doi250045r22","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/j.1365-2133.2009.09341.x","article-title":"Tolerability of high-dose topical tretinoin: the Veterans Affairs Topical Tretinoin Chemoprevention Trial.","volume":"161","author":"Geng","year":"2009","journal-title":"Br J Dermatol"},{"issue":"6","key":"doi250045r23","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jaad.2017.11.062","article-title":"Skin cancer in the military: a systematic review of melanoma and nonmelanoma skin cancer incidence, prevention, and screening among active duty and veteran personnel.","volume":"78","author":"Riemenschneider","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"doi250045r24","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1038\/jid.2015.238","article-title":"Skin cancer risk factors and preventative behaviors among United States military veterans deployed to Iraq and Afghanistan.","volume":"135","author":"Powers","year":"2015","journal-title":"J Invest Dermatol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2838591\/jamadermatology_breglio_2025_oi_250045_1762976594.09017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T16:00:42Z","timestamp":1763568042000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2838591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2025.3238","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,1]]}}}